CD274 and neoplasm: Previous studies have recognized patient subsets who might benefit from immune checkpoint monotherapies, including those with high PD-L1 expression, hypermutation or high microsatellite instability, abundant germline/somatic DNA-repair gene mutations, intraductal/ductal histology, AR-V7-positive tumors however, it was still insufficient and these indicators could not adequately reflect the state of tumor immune microenvironment (Isaacsson Velho and Antonarakis, 2018; Vitkin et al., 2019).